SWM
CDIO icon

SHP Wealth Management’s Cardio Diagnostics CDIO Stock Holding History

SHP Wealth Management’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31 Hold
16
– – ﹤0.01% 1800
2025
Q4 		$43 Buy
+16
New +$58 ﹤0.01% 1528

Other funds holding CDIO

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SHP Wealth Management's CDIO Position: Q1 2026 in Review

SHP Wealth Management held its Cardio Diagnostics (CDIO) position steady in Q1 2026 at 16 shares worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #1800.

SHP Wealth Management first reported a position in CDIO in Q4 2025 and has held it in 2 quarters since. The position peaked at $43 in Q4 2025. 16 funds tracked by Wall St. Rank hold CDIO as of Q1 2026.

  • SHP Wealth Management held 16 shares of Cardio Diagnostics worth $31 as of Q1 2026.
  • SHP Wealth Management left its Cardio Diagnostics share count unchanged in Q1 2026.
  • Cardio Diagnostics made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1800 holding.
  • SHP Wealth Management first reported a position in Cardio Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • SHP Wealth Management's Cardio Diagnostics position peaked at $43 in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.